IRD · ISSUER CIK 1228627
Opus Genetics, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 6 Opus Genetics, Inc. insiders reported $0.00 of open-market purchases and $3.1M of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. 2 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$3.1MInsider selling
−$3.1MNet open-market
Oct 27, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 202616:47 | Oct 23, 2026 | IRD | Chief Operating Officer | S · Sell | $3.57 | −4,767 | 286,673 | -2% | −$17K | ||
| Oct 27, 202616:41 | Oct 23, 2026 | IRD | President, Director | S · Sell | $3.54 | −33,189 | 670,917 | -5% | −$117K | ||
| Oct 27, 202616:29 | Oct 23, 2026 | IRD | Chief Financial Officer | S · Sell10b5-1 | $3.55 | −14,000 | 542,375 | -3% | −$50K | ||
| Oct 27, 202616:20 | Oct 23, 2026 | IRD | Chief Executive Officer, Director | S · Sell | $3.59 | −9,591 | 2,038,894 | -0% | −$34K | ||
| Oct 2, 202619:47 | Sep 30, 2026 | IRD | Director, See Remarks · +1 joint | S · Sell | $4.96 | −556,000 | 3,236,171 | -15% | −$2.8M | ||
| Sep 11, 202616:09 | Sep 9, 2026 | IRD | Chief Executive Officer, Director | M · Exercise | $1.15 | +392,157 | 2,124,026 | +23% | $451K | ||
| Sep 11, 202616:09 | Sep 9, 2026 | IRD | Chief Executive Officer, Director | F · Tax | $5.97 | −75,541 | 2,048,485 | -4% | $451K | ||
| Sep 8, 202616:05 | Sep 8, 2026 | IRD | Director | M · Exercise | $1.15 | +784,314 | 2,800,111 | +39% | $902K | ||
| Sep 8, 202616:05 | Sep 3, 2026 | IRD | Chief Financial Officer | S · Sell10b5-1Late 5d | $4.54 | −28,000 | 556,375 | -5% | −$127K |